The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Open accessAbstract
Objective: To examine interactions of apolipoprotein E ( APOE) genotype with age and with in vivo measures of preclinical Alzheimer disease (AD) in cognitively normal aging. Methods: Two hundred forty‐one cognitively normal individuals, aged 45–88 years, had cerebral amyloid imaging studies with Pittsburgh Compound‐B (PIB). Of the 241 individuals, 168 (70%) also had cerebrospinal fluid (CSF) assays of amyloid‐beta 42 (Aβ 42 ), tau, and phosphorylated tau (ptau 181 ). All individuals were genotyped for APOE . Results: The frequency of individuals with elevated mean cortical binding potential (MCBP) for PIB rose in an age‐dependent manner from 0% at ages 45–49 years to 30.3% at 80–88 years. Reduced levels of CSF Aβ 42 appeared to begin earlier (18.2% of those aged 45–49 years) and increase with age in higher frequencies (50% at age 80–88 years) than elevations of MCBP. There was a gene dose effect for the APOE4 genotype, with greater MCBP increases and greater reductions in CSF Aβ 42 with increased numbers of APOE4 alleles. Individuals with an APOE2 allele had no increase in MCBP with age and had higher CSF Aβ 42 levels than individuals without an APOE2 allele. There was no APOE4 or APOE2 effect on CSF tau or ptau 181 . Interpretation: Increasing cerebral Aβ deposition with age is the pathobiological phenotype of APOE4 . The biomarker sequence that detects Aβ deposition may first be lowered CSF Aβ 42 , followed by elevated MCBP for PIB. A substantial proportion of cognitively normal individuals have presumptive preclinical AD. ANN NEUROL 2010;67:122–131
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The association of the APOE4 isoform with amyloid deposition has been well established in human studies, where APOE4 carriers exhibit higher A β plaque burden and earlier onset of amyloid positivity compared with non-carriers 35 -37 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE status has been found to modulate the onset of extracellular amyloid plaque deposition, one of the key pathognomonic features of the disease (6, 7).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“On the basis of previous studies (7, 27), individuals with mean cortical binding potential (MCBP) for PIB >0.18 were considered PIB-positive (PIB+).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Given that a CSF Aβ42 concentration lower than 500 pg/mL has been utilized as a reliable threshold for the presence of cerebral Aβ deposition in humans (7, 19, 22, 26)”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Increasing age and ApoE genetic background are the strongest known risk factors for AD and plaque load (33, 48); thus it was critical that these parameters were controlled.”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“Sex differences in Aβ burden alone have not been reported in older adults,11–13”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [13]
In the citing paper
“Previous cross-sectional studies indicate that Aβ42 levels decrease in the CSF as Aβ starts to accumulate, before fibrillar plaques can be detected with PET7–11.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,345
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Flagged first, then by citations
1 of the 80 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 701–800 of 835
Grey Matter and Cognitive Patterns in Cognitive Impaired Subjects Using CSF Biomarker Cut-Offs
Miralbell, J., Spulber, G., Hooshmand, B., Besga, A., Mataró, M., Cedazo-Mı́nguez, Á., Kivipelto, M., & Wahlund, L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111553 · Cited by 3
At the crossroads of preclinical AD and normal brain ageing
Okonkwo, O. C. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70207-8 · Cited by 3
Robert, J., Cheng, W. H., Hayat, A., Ward-Able, T., & Wellington, C. L. (2015) · Clinical Lipidology · doi:10.2217/clp.14.64 · Cited by 3
Neuropathology of HIV-1 Disease
Soontornniyomkij, V. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7290-6_8 · Cited by 3
Amyloid Imaging in Dementia and Neurodegenerative Disease
Ponisio, M. R., Iranpour, P., & Benzinger, T. L. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-82367-2_11 · Cited by 4
Theta band-power shapes amyloid-driven longitudinal EEG changes in pre-clinical Alzheimer’s DiseasePreprint
Spinelli, G., Bakardjian, H., Schwartz, D., Potier, M., Habert, M., Lévy, M., Dubois, B., & George, N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.04.479130 · Cited by 3
Aschenbrenner, A. J., Jackson, J. J., & Hassenstab, J. J. (2023) · doi:10.31234/osf.io/synrd · Cited by 3
Naturalistic Assessment of Reaction Time Variability in Older Adults at Risk for Alzheimer DiseasePreprint
Welhaf, M., Aschenbrenner, A. J., Wilks, H., & Hassenstab, J. J. (2023) · doi:10.31234/osf.io/j7ed2 · Cited by 3
Seo, D., Lee, C. M., Apio, C., Heo, G., Timsina, J., Kohlfeld, P., Boada, M., Orellana, A., Fernández, M. V., Ruiz, A., et al. (2024) · medRxiv · doi:10.1101/2024.06.18.24309102 · Cited by 3
Self-citationVanderlip, C. R., & Stark, C. E. L. (2025) · Neurology · doi:10.1212/wnl.0000000000213853 · Cited by 2
Song, W., Gong, C., Li, Y., Yang, D., Chen, H., Tang, L., Xu, Y., & Zhao, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251389965 · Cited by 2
A Call for New Thoughts About What Might Influence Human Brain Aging
DeCarli, C. S. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.33 · Cited by 2
Subsets of a Large Cognitive Battery Better Power Clinical Trials on Early Stage Alzheimer's Disease
Xiong, C., Weng, H., Bennett, D. A., Boyle, P. A., Shah, R. C., Fague, S., Hall, C. B., Lipton, R. B., & Morris, J. C. (2014) · Neuroepidemiology · doi:10.1159/000365733 · Cited by 2
Self-citationGuen, Y. L., Belloy, M. E., Grenier‐Boley, B., de Rojas, I., Castillo-Morales, A., Jansen, I. E., Nicolas, A., Bellenguez, C., Dalmasso, C., Küçükali, F., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.060114 · Cited by 2
A Toxicogenic Interaction between Intracellular Amyloid-β and Apolipoprotein-E
Dey, A., Verma, A., Bhaskar, U., Sarkar, B., Kallianpur, M., Vishvakarma, V., Das, A. K., Garai, K., Mukherjee, O., Ishii, K., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00048 · Cited by 3
Platero, C. A., Tohka, J., & Strange, B. A. (2023) · Current Alzheimer Research · doi:10.2174/0115672050295317240223162312 · Cited by 2
ALZHEIMER HASTALIĞI, RİSK FAKTÖRLERİ VE TEDAVİ
Yıldırım, N., & Eke, B. C. (2024) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1441827 · Cited by 4
Zhuang, X., Xu, G., Amei, A., Cordes, D., Wang, Z., Oh, E. C. T., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12597 · Cited by 2
Gong, L., Liu, D., Zhang, B., Yu, S., & Xi, C. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04243-z · Cited by 2
Shao, K., Chen, X., Yu, X., Yang, J., Wei, M., Zhang, M., Li, R., Wang, X., Wei, Y., Yan, C., et al. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241291236 · Cited by 2
Whole-genome sequencing reveals the impact of lipid pathway and APOE genotype on brain amyloidosis
Patel, M., Pottier, C. P., Fan, K.-H., Cetin, A., Johnson, M., Ali, M., Liu, M., Gorijala, P., Budde, J., Shi, R., et al. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddaf017 · Cited by 2
Self-citationMorito, T., Watamura, N., Sasaguri, H., Tomita, T., Higuchi, M., Okano, H., Sasaki, E., & Saido, T. C. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251321116 · Cited by 2
Quantifying an amyloid β model for Alzheimer's disease
Schneider, L. S. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70050-4 · Cited by 2
Molchan, S. E. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.748 · Cited by 2
Amyloid imaging in Alzheimer’s disease: a potential new era of personalized medicine?
Leuzy, A., Zimmer, E. R., Gauthier, S. G., & Rosa‐Neto, P. (2014) · Translational Neuroscience · doi:10.2478/s13380-014-0205-y · Cited by 2
Amyloid imaging for Alzheimer's disease
Kerchner, G. A. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.617365 · Cited by 2
Huang, S., Zhu, J., Shen, X., Xu, W., Ma, Y., Li, H., Dong, Q., Tan, L., & Yu, J. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200059 · Cited by 2
Ko, H., Park, S., Kwak, S., & Ihm, J. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040197 · Cited by 2
[18F] FBB cortical uptake is not related to the age of onset of Alzheimer’s disease
Chiaravalloti, A., Barbagallo, G., Castellano, A. E., Ricci, M., Ciccariello, G., Ursini, F., D’Ascenzo, N., Xie, Q., & Schillaci, O. (2019) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001131 · Cited by 2
Korthauer, L. E., Blujus, J. K., Awe, E., Frahmand, M., Prost, R. W., & Driscoll, I. F. (2021) · Brain Imaging and Behavior · doi:10.1007/s11682-021-00573-x · Cited by 2
Pomara, N., & Bruno, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114219108 · Cited by 2
Mediation Analysis in Understanding Mechanism of Alzheimer’s Disease Risk
Sajeev, G. (2015) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 2
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions
Villemagne, V. L., Doré, V., Burnham, S. C., & Rowe, C. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_10 · Cited by 2
de Havenon, A., Littig, L., Clocchiatti‐Tuozzo, S., Johnson, I. P., Constantinescu, S., Rivier, C. A., Huo, S., Kimberly, W. T., Gómez‐Isla, T., Kim, Y., et al. (2025) · Annals of Neurology · doi:10.1002/ana.78103 · Cited by 1
Protective mutations associated with APOE in Alzheimer’s disease
Ma, Y., Li, Y., Wu, G., Liu, L., Tian, M., Han, X., Chen, X., Xuan, X., Zheng, T., Gao, X., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03496-5 · Cited by 1
Cell-type-specific APOE4 cascade across the Alzheimer’s disease continuum
Shostak, D. M., Liang, Z., & Huang, Y. (2026) · Neuron · doi:10.1016/j.neuron.2026.04.024 · Cited by 1
APOE, Human Ancestry, and Evolution
Smith, C. J., Ashford, J. W., & Perfetti, T. A. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_4 · Cited by 1
Davis, R., Wood, L., Wilkes, L., Chandler, H. L., Anderson, E. L., & Hiscox, L. V. (2026) · NeuroImage Clinical · doi:10.1016/j.nicl.2026.104035 · Cited by 1
Stover, K. R. (2015) · DalSpace (Dalhousie University) · Cited by 1
Möglichkeiten moderner Bildgebungstechnologien im Rahmen der Frühdiagnostik von Alzheimererkrankung
Unschuld, P. G. (2015) · Therapeutische Umschau · doi:10.1024/0040-5930/a000674 · Cited by 1
Future Perspectives of Alzheimer Disease Research
Iwatsubo, T. (2011) · TRENDS IN THE SCIENCES · doi:10.5363/tits.16.7_57 · Cited by 1
Applications of fMRI to Neurodegenerative Disease
Mahmoud, S. Y., Moon, D., Lee, J. K., & Jones, S. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-10909-6_36 · Cited by 1
Alzheimer’s Disease Aβ-Amyloid Plaque Morphology Varies According to APOE Isotype
Caesar, I., Nilsson, K. P. R., Hammarström, P., Lindgren, M., Prokop, S., Schmeidler, J., Haroutunian, V. H., Holtzman, D. M., Hof, P. R., & Gandy, S. (2023) · World Journal of Neuroscience · doi:10.4236/wjns.2023.133008 · Cited by 1
Self-citationLeclerc, H., Lee, A. K., Kunicki, Z. J., & Alber, J. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241283692 · Cited by 1
Functional and Structural MRI in Alzheimer’s Disease: A Multimodal Approach
Grothe, M. J., Bokde, A. L. W., & Teipel, S. J. (2014) · Springer eBooks · doi:10.1007/978-3-642-54542-9_20 · Cited by 1
Pilot study of a new road test to assess cognitive fitness to drive
Vanlaar, W. G. M., Hing, M. M., Meister, S. R., Charles, J.-M., Ireland, L., Mayhew, D. R., Carr, D., Barco, P. P., & Robertson, R. D. (2019) · Transportation Research Part F Traffic Psychology and Behaviour · doi:10.1016/j.trf.2019.07.022 · Cited by 1
Sex effects in predictors of memory resilience for carriers of Alzheimer’s genetic risk
McDermott, K. L. (2016) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3st7f49f · Cited by 1
Patel, P. S., Bernard, M. A., & Masurkar, A. V. (2024) · medRxiv · doi:10.1101/2024.08.04.24311473 · Cited by 1
Chen, K., Chen, Y., Ren, Y., Wang, Z., Huang, Y., Pan, M., Li, Z., Casey, M. C., Qiao, W., Shi, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-78407-x
Self-citationVirta, J. J. (2012) · UTUPub (University of Turku)
The Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s
Alzheimer’s Disease Genomics and Clinical Applications
Lee, T.-S. W., & Sian, M. (2011) · InTech eBooks · doi:10.5772/18773
Mechanisms of Brain Region-Specific Amyloid-beta Deposition
Bero, A. W. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7cj8bh2
Modulating Amyloid Beta Clearance by Altering Cellular and Whole Brain Apolipoprotein E Metabolism
Basak, J. M. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7dz06bk
Balasa, M. (2013) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Isotyping the Human TOMM40 Variable-Length Polymorphism by Gene Amplification and Restriction Digest
Greco, S. J., Hamzelou, A., Johnston, J. M., Richardson, S. L., Smith, M. A., Perry, G. L., Ashford, J. W., & Tezapsidis, N. (2012) · Current Alzheimer Research · doi:10.2174/156720512804142921
Pet Amyloid Imaging: Can Its Diagnostic Potential Be Effectively Realized in the clinic?
Fleisher, A., & Wolk, D. A. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.73
Shi, Z., Ying, W., Liu, S., Liu, S., Zhou, Y., Wang, J., Gao, S., & Ji, Y. (2014) · DOAJ (DOAJ: Directory of Open Access Journals)
Price, J. C., Lopresti, B. J., & Villemagne, V. L. (2012) · Neuromethods · doi:10.1007/7657_2012_47
Interview with Dr John Morris, 28 February 2013
Katz, S., & Peters, K. R. (2014) · Dementia · doi:10.1177/1471301214562142
Ikonomovic, M. D., Abrahamson, E. E., Paljug, W. R., Klunk, L. W. E., Debnath, M. L., Cohen, A. D., Klunk, W. E., Price, J. C., Mathis, C. A., Hamilton, R. L., et al. (2012)
Towards the Preclinical Treatment of Alzheimer Disease.
Iwatsubo, T. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.2089
Nye diagnosekriterier for Alzheimers sykdom
Aarsland, D., Rongve, A., Fladby, T., Testad, I., Kivipelto, M., & Winblad, B. G. (2011) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.11.1028
Neuroethics : what else is new?
Mauron, A. (2010) · Archive ouverte UNIGE (University of Geneva)
Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1
Self-citationQuantifying an amyloid β model for Alzheimer's disease
Paterson, L. (2013)
Tsolaki, A. (2015) · Advances in psychology, mental health, and behavioral studies (APMHBS) book series · doi:10.4018/978-1-4666-8234-4.ch002
Memory decline and Aβ amyloid as markers of neurodegeneration in preclinical Alzheimer's disease
Lim, Y. Y. (2013) · Minerva Access (University of Melbourne)
Kapadia, F. (2016) · TSpace (University of Toronto)
Neurocognitive Plasticity: A Longitudinal Study of Memory Training and White Matter Microstructure
de Lange, & Glasø, A.-M. D. L. (2017)
Featured Articles The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L. S., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Pontecorvo, M. J., Rowe, C. C., et al. (2015)
Self-citationModifiable risk factors moderate the relationship between beta-amyloid and cognition in midlifePreprint
Clark, L. R., Koscik, R. L., Allison, S. L., Berman, S. E., Carlsson, C. M., Norton, D., Bendlin, B. B., Asthana, S., Betthauser, T. J., Christian, B. T., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/229062
Statistical Analyses to Detect and Refine Genetic Associations with Neurodegenerative Diseases
Katsumata, Y. (2017) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2017.486
Assessing Cognition In A Mouse Model Of Alzheimer’s Disease
Mels, J. (2018) · Scholarship@Western (Western University)
Amyloid-β PET Imaging in Aging and Dementia
Tolboom, N., Ossenkoppele, R., & van Berckel, B. N. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-01523-7_11
Biomarkers for Alzheimer's disease and the APOE polymorphism
Lautner, R. (2019) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Risk factors for development of neurocognitive disorders
Gustavsson, A. (2019) · Lund University Publications (Lund University)
Wang, Z. (2019) · Biostatistics & Epidemiology · doi:10.1080/24709360.2019.1673623
Molecular determinants of astrocyte morpho-functional changes in Alzheimer’s disease
Ulzheimer, N. E. (2019) · CLOK (University of Central Lancashire)
Genetic and functional studies of genes involved in the pathogenesis of Alzheimer's disease
Natunen, T. (2014) · UEF eRepo (University of Eastern Finland)
Silva, E. M. F. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2020.tde-05062020-084321
Farrer, T., & Cook, S. E. (2021) · Advances in neuroethics · doi:10.1007/978-3-030-62073-8_6
Assadpour, S., Shiran, M. R., & Akhtari, J. (2021) · DOAJ (DOAJ: Directory of Open Access Journals)
Яхьяевич, Я. Н., & Vagabov, N. M. (2009) · VESTNIK OF ASTRAKHAN STATE TECHNICAL UNIVERSITY SERIES MARINE ENGINEERING AND TECHNOLOGIES
Carrasquillo, M. M., Bu, G., & Nielsen, H. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7309-1_2
Current awareness in geriatric psychiatry
(2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2397
Saint‐Aubert, L. (2012) · Thèses en ligne de l'Université Toulouse III (Université Toulouse III)
Cellular Mechanisms of Dementia
Gan, L. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0054
Identifying genetic variants for amyloid β in subcortical vascular cognitive impairment
Kim, H., Jung, S., Kim, B., Kim, J., Jang, H., Kim, J. P., Kim, S. Y., Na, D. L., Kim, H. J., Nho, K. T., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1160536
Alzheimer’s Research Gains Momentum and Spreads Out
Behl, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-31570-1_14
Yu, M., Risacher, S. L., Nho, K. T., Wen, Q., Oblak, A. L., Unverzagt, F. W., Apostolova, L. G., Farlow, M. R., Brosch, J. R., Clark, D. G., et al. (2023) · medRxiv · doi:10.1101/2023.08.12.23294017
Apolipoprotein-E transforms intracellular Amyloid-β oligomers to a more toxic statePreprint
Dey, A., Verma, A., Bhaskar, U., Sarkar, B., Kallianpur, M., Vishvakarma, V., Das, A. K., Garai, K., Mukherjee, O., Ishii, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.03.556061
Detecting time-varying genetic effects in Alzheimer’s disease using a longitudinal GWAS modelPreprint
Zhuang, X., Xu, G., Amei, A., Cordes, D., Wang, Z., Oh, E. C. T., & Initiative, A. D. N. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.17.562756
Hsieh, Y., Negri, J. M., He, A., Pearse, R. V., Liu, L., Duong, D. M., Chibnik, L. B., Bennett, D. A., Seyfried, N. T., & Young‐Pearse, T. L. (2022) · Figshare · doi:10.6084/m9.figshare.21185043
Hsieh, Y., Negri, J. M., He, A., Pearse, R. V., Liu, L., Duong, D. M., Chibnik, L. B., Bennett, D. A., Seyfried, N. T., & Young‐Pearse, T. L. (2022) · Figshare · doi:10.6084/m9.figshare.21185040
Hsieh, Y., Negri, J. M., He, A., Pearse, R. V., Liu, L., Duong, D. M., Chibnik, L. B., Bennett, D. A., Seyfried, N. T., & Young‐Pearse, T. L. (2022) · Figshare · doi:10.6084/m9.figshare.21185046
Ugwuanyi, I., Oladoyin, I. A., Anazor, C. V., Dike, I. D., Ezulu, P. C., & Nwagbata, A. (2024) · African Journal of Mathematics and Statistics Studies · doi:10.52589/ajmss-4wnit6f9
Metadata
- Authors
- Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Morris, John C.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 67
- Issue
- 1
- Pages
- 122-131
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC2830375
- OpenAlex
- W2014897304
- Cited by
- 830
- References
- 80
- Citations by year
- 2026: 21 · 2025: 23 · 2024: 38 · 2023: 39 · 2022: 54 · 2021: 40 · 2020: 53 · 2019: 53 · 2018: 49 · 2017: 58 · 2016: 54 · 2015: 48 · 2014: 65 · 2013: 76 · 2012: 63
- FWCI
- 32.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000448)
- National Institute on Aging (P50AG005681, P01AG003991, P01AG026276)
- National Center for Research Resources (UL1RR024992)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- apolipoprotein E, APOE ε4, APOE2, amyloid-beta, tau protein, preclinical Alzheimer's disease, Pittsburgh compound B, cerebrospinal fluid biomarkers, gene dosage effect, phosphorylated tau
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Aniline Compounds, Apolipoproteins E, Brain, Female, Follow-Up Studies, Genotype, Humans, Longitudinal Studies, Male, Middle Aged, Peptide Fragments, Phosphorylation, Thiazoles, Amyloid beta-Peptides, tau Proteins, Apolipoprotein E4, Apolipoprotein E2, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
